Metastatic melanoma: Newer TKIs and immune checkpoint inhibitors lead the way in survival
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
- In an explorative analysis of different studies in metastatic melanoma, the optimal survival outcomes were observed with combination BRAF and MEK inhibition, or immune checkpoint inhibition.
- Explorative analysis comparing survival data from different clinical trials of current interest in metastatic melanoma.
- 35 Kaplan-Meier curves (PFS, OS, or both) from 17 Phase I-III clinical trials were included.
- Average 12-month OS in 1L: BRAFi + MEKi: 74.5%; PD-1 inhibition: 71.9%.